CytomX Therapeutics (CTMX) Accounts Payables (2014 - 2026)

CytomX Therapeutics (CTMX) has 13 years of Accounts Payables data on file, last reported at $1.4 million in Q1 2026.

• Quarterly Accounts Payables rose 395.65% year-over-year to $1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 million (up 395.65% YoY) and the FY2025 annual result came in at $1.3 million, up 19.58% from the prior year.
• Accounts Payables advanced to $1.4 million in Q1 2026, from $1.3 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $5.2 million in Q3 2022 to a low of $227000.0 in Q2 2025.
• A 5-year average of $1.6 million and a median of $1.4 million in 2024 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2025 — Accounts Payables slumped 85.95% — and 2026, when it surged 395.65%.
• Tracing CTMX's Accounts Payables over 5 years: stood at $2.8 million in 2022, then tumbled by 48.1% to $1.5 million in 2023, then slipped by 25.38% to $1.1 million in 2024, then rose by 19.58% to $1.3 million in 2025, then advanced by 5.15% to $1.4 million in 2026.
• The last three Accounts Payables figures came in at $1.4 million (Q1 2026), $1.3 million (Q4 2025), and $646000.0 (Q3 2025), per Business Quant data.